Pharmacokinetic/pharmacodynamic modeling of the antinociceptive effects of (+)-tramadol in the rat: Role of cytochrome P450 2D activity

Journal of Pharmacology and Experimental Therapeutics

Volumn 305, Issue 2, 2003, Pages 710-718

  Garrido, María J ^a   Sayar, Onintza ^a   Segura, Cristina ^a   Rapado, Javier ^a   Dios Viéitez, María Carmen ^a   Renedo, María Jesús ^a   Trocóniz, Iñaki F ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D; O NORTRAMADOL; QUININE; TRAMADOL; UNCLASSIFIED DRUG;

ANALYTICAL ERROR; ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; ELIMINATION REACTION; MALE; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT;

ALGORITHMS; ANALGESICS, OPIOID; ANIMALS; BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP2D6; ENZYME INHIBITORS; INFUSIONS, INTRAVENOUS; MALE; MODELS, BIOLOGICAL; QUININE; RATS; RATS, WISTAR; TRAMADOL;

EID: 0037405133     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.047779     Document Type: Article

References (29)

1. Abdel-Rahman SM, Marcucci K, Boge T, Gotschall RR, Kearns GL, and Leeder JS (1999) Potent inhibition of cytochrome P-450 2D6-mediated dextromethorphan O-demethylation by terbinafine. Drug Metab Dispos 27:770-775.
2. Al-Dabbagh SG, Idle JR, and Smith RL (1981) Animal modelling of human polymorphic drug oxidation - the metabolism of debrisoquine and phenacetin in rat inbred strains. J Pharm Pharmacol 33:161-164.
3. Beal SL and Sheiner LB (1992) NONMEM User's Guide. NONMEM Project Group, University of California, San Francisco.
4. Bertilsson L, Lou YQ, Du YL, Liu Y, Kuang TY, Liao XM, Wang KY, Reviriego J, Iselius L, and Sjöqvist F (1992) Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquine and S-mephenytoin. Clin Pharmacol Ther 51:388-397.
5. Brynne N, Forslund C, Hallén B, Gustafsson LL, and Bertilsson L (1999) Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity. Br J Clin Pharmacol 48:564-572.
6. Campanero MA, Calahorra B, Valle M, Troconiz IF, and Hororato J (1999) Enantiomeric separation of tramadol and its active metabolite in human plasma by chiral high-performance liquid chromatography: application to pharmacokinetic studies. Chirality 11:272-279.
7. Clement EM, Grahame-Smith DG, and Elliot JM (1998) Investigation of the presynaptic effects of quinine and quinidine on the release and uptake of monoamines in rat brain tissue. Neuropharmacology 37:945-951.
8. D'Amour FE and Smith DL (1941) A method for determining loss of pain sensation. J Pharmacol Exp Ther 72:74-769.
9. Frink MCH, Hennies HH, Englberger W, Haurand M, and Wilffert B (1996) Influence of tramadol on neurotransmitter systems of the rat brain. Arzneim-Forsch/Drug Res 46:1029-1036.
10. Gårdmark M, Brynne L, Hammarlund-Udenaes M, and Karlsson MO (1999) Interchangeability and predictive performance of empirical tolerance models. Clin Pharmacokinet 36:145-167.
11. Garrido MJ, Valle M, Campanero MA, Calvo R, and Trocóniz IF (2000) Modeling of the in vivo antinociceptive interaction between an opioid agonist, (+)-O-demethyltramadol and a monoamine reuptake inhibitor, (-)-O-demethyltramadol, in rats. J Pharmacol Exp Ther 295:352-359.
12. Kahn GC, Rubenfield M, Davies DS, Murray S, and Boobis AR (1985) Sex and strain differences in hepatic debrisoquine 4-hydroxylase activity of the rat. Drug Metab Dispos 13:510-516.
13. Klein JP and Moeschberger ML (1997) Survival Analysis. Techniques for Censored and Truncated Data, Springer-Verlag, New York.
14. Kobayashi S, Murray S, Watson D, Sesardic D, Davies DS, and Boobis AR (1989) The specificity of inhibition of debrisoquine 4-hydroxylase activity by quinidine and Q in the rat is the inverse of that in man. Biochem Pharmacol 38:2795-2799.
15. Lai J, Ma S, Porreca F, and Raffa RB (1996) Tramadol, M1 metabolite and enantiomer affinities for cloned human opioid receptors expressed in transfected HN9.10 neuroblastoma cells. Eur J Pharmacol 316:369-372.
16. Le Bars D, Gozariu M, and Cadden SW (2001) Animal models of nociception. Pharmacol Rev 53:597-652.
17. Lintz W, Erlacin S, Frankus E, and Uragg H (1981) Metabolismus von Tramadol bei Mensch und Tier. Arzneim-Forsch/Drug Res 31:1932-1943.
18. Luks AM, Zwass MS, Brown RC, Lau M, Chari G, and Fisher DM (1998) Opioid-induced analgesia in neonatal dogs: pharmacodynamic differences between morphine and fentanyl. J Pharmacol Exp Ther 284:136-141.
19. Paar WD, Frankus P, and Dengler HJ (1992) The metabolism of tramadol by human liver microsomes. Clin Investig 70:708-710.
20. Paar WD, Poche S, Gerloff J, and Dengler HJ (1997) Polymorphic CYP2D6 mediates O-demethylation of the opioid analgesic tramadol. Eur J Clin Pharmacol 53:235-239.
21. Poulsen L, Arendt-Nielsen L, Brøsen K, and Sindrup SH (1996) The hypoalgesic effect of tramadol in relation to CYP2D6. Clin Pharmacol Ther 60:636-644.
22. Raffa RB and Friderichs E (1996) The basic science aspect of tramadol hydrochloride. Pain Rev 3:249-271.
23. Raffa RB, Friderichs E, Reimann W, Shank RP, Codd EE, and Vaught JL (1992) Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an "atypical" opioid analgesic. J Pharmacol Exp Ther 260:275-285.
24. Raffa RB, Nayak RK, Liao S, and Minn FL (1995) The mechanism(s) of action and pharmacokinetics of tramadol hydrochloride. Rev Contemp Pharmacother 6:485-497.
25. Rhoda CL, McTavish D, and Sorkin EM (1993) Tramadol. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in acute and chronic pain states. Drugs 46:313-340.
26. Sheiner LB, Stanski DR, Vozeh S, Miller RD, and Ham J (1979) Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 25:358-371.
27. Steimer JL, Mallet A, Golmard JL, and Boisvieux JF (1984) Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed-effect model. Drug Metab Rev 15:265-292.
28. Tomkins DM, Otton SV, Joharchi N, Li N-Y, Balster RF, Tyndale RF, and Sellers EM (1997) Effect of cytochrome P450 2D1 inhibition on hydrocodone metabolism and its behavioral consequences in rats. J Pharmacol Exp Ther 280:1374-1382.
29. Valle M, Garrido MJ, Pavón JM, Calvo R, and Trocóniz IF (2000) Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effects of main active metabolites of tramadol, (+)-O-demethyltramadol and (-)-O-demethyltramadol, in rats. J Pharmacol Exp Ther 293:646-653.